Exploring Pharmacogenomic Testing in MDD

<p>Can pharmacogenomic testing improve the selection and dosing of antidepressants in patients with MDD? In this episode, we explore the findings of the PRIME Care trial and discuss the clinical significance of these tests. </p> <p>Faculty: Jim Phelps, M.D.<br /> Host: Richard Seeber, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC268" target="_blank" rel="noopener"><strong>Learn more about our membership here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-49-2707?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC268" target="_blank" rel="noopener"><strong>Earn 0.5 CMEs: Quick Take Vol. 49</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/effect-of-pharmacogenomic-testing-for-druggene-interactions-on-medication-selection-and-remission-of-symptoms-in-major-depressive-disorder-the-prime-care-randomized-clinical-trial-2707-5433?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC268" target="_blank" rel="noopener"><strong>Effect of Pharmacogenomic Testing for Drug–Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial</strong></a><br /> <br /></li> </ul>